Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04987164
Other study ID # C1671
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 18, 2021
Est. completion date August 4, 2022

Study information

Verified date February 2023
Source CEN Biotech
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Cranberries are traditionally used for urinary comfort and prevention of urinary disorders of bacterial origin and despite an EFSA opinion invalidating the clinical efficacy of cranberries, its mechanism of action has been several times proposed by the scientific community: it would act by inhibiting the synthesis of P-fimbriae leading to a complete disappearance of these adhesins, and to bacterial-type deformation by lengthening of the cell body. Cinnamon and microbiotic strains could enhance this synergy. This study aims to evaluate the effectiveness of a food supplement based on cranberry, cinnamon and microbiotic strains (Feminabiane CBU) on the symptoms of cystitis, urinary discomfort and the number of cystitis reported by women.


Description:

Women who use or not the cranberry, cinnamon, and microbiotic blend are encouraged to complete a 6-month diary in which they report any urinary tract disorders they encounter.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date August 4, 2022
Est. primary completion date August 4, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Having at least 2 symptomatic episodes of cystitis during the last 6 months including at least 1 episode confirmed as being bacterial cystitis (by an urine bacterial analysis or validated by a doctor (date of appointment, list of prescribed treatments) ; - Whose symptomatic episodes of cystitis over the past 6 months have had a significant impact on quality of life / urinary comfort (ACSS QoL> 2); - Having a smartphone compatible with the NURSTRIAL® data collection application; - Not opposing the collection and processing of their personal data. Exclusion Criteria: - Presenting urinary discomfort with a severe impact on quality of life (ACSS QoL> 7) during the last 24 hours prior to inclusion; - Pregnant, breastfeeding or planning to become pregnant during the study; - Under antibiotic treatment (or during the last month preceding inclusion); - Under food supplementation with prebiotics or probiotics or having stopped it less than a month before inclusion; - Having had recourse to a prophylactic treatment (cranberry juice) 15 days before inclusion; - Having had local estrogen therapy during the 3 months preceding inclusion; - Diabetic; - Presenting an immunosuppressive disease; - Presenting pelvic floor abnormalities (Cystocele surgery, etc.); - Presenting or having a history of kidney disease (including kidney stones, urinary tract abnormalities, pyelonephritis, kidney failure, kidney transplantation); - For women consuming supplementation: known allergy to plants of the cranberry family or to one of the components of the products.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Feminabiane CBU
EXTRACTS OF CRANBERRY, CINNAMON AND MICROBIOTIC STRAINS

Locations

Country Name City State
France CEN Nutriment Dijon Bourgogne
France CEN Nutriment Dijon Burgundy

Sponsors (2)

Lead Sponsor Collaborator
CEN Biotech PiLeJe

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Other Assessing the remanent effect of the mix on total urinary tract disorders Total number of urinary tract disorders reported by women, compared to the 0-24 week period At week 32
Other Assessing the remanent effect of the mix on the type urinary tract disorders Rates of urinary tract disorders (cystitis and cystitis-like symptoms) reported by women, compared to the 0-24 week period At week 32
Other Satisfaction with the assessed mix Mean statisfaction score using a 5-point Likert scale: 1 means worse satisfaction and 5 means the best satisfaction.
Very satisfied=1, Somewhat satisfied=2, Neither satisfied nor dissatisfied=3, Somewhat dissatisfied=4 and Very dissatisfied=5
At month 1, 2, 3, 4, 5, 6
Other Dietary supplementation ingestion observance Weekly number of food supplements not ingested in relation to the expected consumption At weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Other Gastrointestinal pain Visual analogic score assessing abdominal pain (0= no pain, 10= worse pain) At weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Other Gastrointestinal discomfort Visual analogic score assessing bloating or flatulence (0= never, 10= always) At weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Other Assessing tolerance to the ingestion of food supplements Total number encountered of adverse events (abdominal pain, bloating, constipation) and rates of this adverse events At week 24
Primary Occurence of symptomatic cystitis-like episodes Number of symptomatic cystitis-like episodes reported by the subject self-assessed using the "typical" domain of the Acute Cystitis Symptom Score (ACCS) and defined by a score ranged between 6 to 18. At week 24
Secondary Change of the quality of life related to urinary discomfort ACCS "Quality of life" domain ranged between 0 (better) and 9 (worse) At weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Secondary Severity of urinary discomfort Global ACCS score ranged between 0 (better) and 39 (worse) Every day during each urinary symptoms (Week 0 to Week 24)
Secondary Time-period without antibiotics Measurement of the time interval between 2 antibiotic therapies if applicable At week 24
Secondary Mean time to onset of symptomatic episodes of the cystitis Measurement of the time interval between 2 symptomatic episodes of the cystitis At week 24
Secondary Effect of blend consumption in preventing symptomatic episode of cystitis Comparison of the rate of women blend users versus non-users who did not reported any symptomatic episode of cystitis as defined by a 0 score for the "typical" domain of the Acute Cystitis Symptom Score (ACCS). At week 24
See also
  Status Clinical Trial Phase
Recruiting NCT04495699 - Asymptomatic Renal Calculi in Recurrent Urinary Tract Infections
Terminated NCT05254808 - EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care Phase 3
Completed NCT03680612 - Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI Phase 2
Completed NCT03282006 - Treating Pyelonephritis an Urosepsis With Pivmecillinam Phase 4
Completed NCT03526484 - The Utility of Urinalysis Prior to In-Office Procedures N/A
Completed NCT05397782 - Effects of Flourish on Recurrent Urinary Tract Infection N/A
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03687255 - Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections Phase 3
Recruiting NCT05227937 - Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
Completed NCT02864420 - Hospitalization at Home: The Acute Care Home Hospital Program for Adults N/A
Completed NCT03131609 - Avoiding Bacterial Contamination of Clean Catch Urine Cultures in Ambulatory Patients in the Emergency Department
Completed NCT01911143 - A Retrospective, Blinded Validation of a Host-response Based Diagnostics N/A
Completed NCT01333254 - A Trial of Different Methods for Bladder Drainage in Hip Surgery Patients N/A
Terminated NCT00594594 - Adjuntive Probiotic Therapy in Treating Urinary Tract Infections in Spinal Cord Injury Phase 1
Completed NCT00216853 - A Study of Vaginal MicroFlora and Immune Profiles of Patients With Recurrent Urinary Tract Infection N/A
Completed NCT00787085 - The Significance of Funguria in Hospitalized Patients N/A
Completed NCT05719753 - The Effectiveness of a Bacteriophobic Coating on Urinary Catheters N/A
Recruiting NCT05415865 - The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder Phase 3
Not yet recruiting NCT05880329 - DIagnoSing Care hOme UTI Study
Recruiting NCT04615065 - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine